Abstract
Colorectal cancer is the second leading cause of cancer death and it is clear that patients with metastatic disease have better quality of life and survival when given treatment. Despite four decades of experience of treating patients with fluorouracil, there remains considerable controversy about the optimum dose and scheduling, as well as biomodulation with leucovorin and methotrexate. However, irrespective of the dose and schedule, overall survival times are poor--about 1 year. Disappointingly, oral agents with similar mechanisms to fluorouracil do not improve survival rates in comparison with fluorouracil and leucovorin treatment. Irinotecan and oxaliplatin are newer agents that have improved the response rates for patients with metastatic disease when they are added to flurouracil and leucovorin. The combination of irinotecan, fluorouracil, and leucovorin has also improved overall survival. These are small advances in the fight against colorectal cancer, and further drug development is necessary.
References
Feb 15, 1992·Cancer·F LéviA Descorps-Declère
Jan 1, 1990·Cancer Chemotherapy and Pharmacology·J M ExtraM Marty
Jun 20, 1990·Journal of the National Cancer Institute·J P CaussanelG Mathé
Mar 20, 1993·BMJ : British Medical Journal·W ScheithauerD Depisch
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F LeviS Iacobelli
Nov 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D CunninghamG Perez-Manga
Jan 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D MachoverM Ychou
Feb 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A de GramontM Krulik
Mar 10, 1998·Japanese Journal of Clinical Oncology·W S WangR K Hsieh
Nov 10, 1998·Lancet·P RougierC Jacques
Nov 10, 1998·Lancet·D CunninghamP Herait
Jan 25, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G K SchwartzM González Barón
Apr 1, 2000·Lancet·J Y DouillardP Rougier
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Jun 11, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C J A PuntC Thielert
Citations
May 9, 2008·International Journal of Clinical Oncology·Satoshi HashinoMasahiro Asaka
Mar 22, 2002·The Lancet Oncology·C TwelvesT Ng
Jun 3, 2004·Annals of Surgical Oncology·Boudewijn van EttenAlexander M M Eggermont
Jun 18, 2004·Cancer Investigation·Ruey-Kuen HsiehJin-Hwang Liu
Jul 31, 2010·Journal of the American College of Surgeons·Matthew F KaladyHemant Ishwaran
Sep 18, 2004·Cancer Letters·Stephanie CarnesecchiFrancis Raul
Apr 22, 2011·Expert Opinion on Drug Delivery·Oliver Dudeck, Jens Ricke
Sep 22, 2007·Chemistry & Biology·Sean D MonahanJon A Wolff
Oct 30, 2010·Cell·Luke A Gilbert, Michael T Hemann
Nov 23, 2005·Oncology·Eduardo Díaz-Rubio, Hans-Joachim Schmoll
Oct 18, 2005·Acta Oncologica·Thomas C YauRichard J Epstein
Oct 9, 2015·PloS One·Anthony J ZachariasKiran K Turaga
Aug 30, 2013·Experimental Biology and Medicine·Steve A Maxwell, Seyed Mousavi-Fard
Dec 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Simone MocellinDonato Nitti
Jun 19, 2004·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·B HildebrandtP Wust
Mar 26, 2008·British Journal of Cancer·G AllegriniG Bocci
Aug 9, 2017·Proceedings of the National Academy of Sciences of the United States of America·Yi Seok ChangTsonwin Hai
Apr 21, 2021·Leukemia Research·Hongyan LiSheng-Yu Jin
Aug 8, 2006·Journal of Proteome Research·Kenneth E HungRaju Kucherlapati